Targeting integrin/CD49D/VLA-4 with natalizumab can inhibit adhesion of malignant B cells and sensitize them to chemoimmunotherapy

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MRÁZ Marek ZENT C. CHURCH A. JELINEK D. POSPÍŠILOVÁ Šárka ANSELL S. NOVAK A. WITZIG T. NOWAKOWSKI G.

Year of publication 2010
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.